\
&
Contact us
\
&
Contact us
Pick a topic from the menu to get started.
On July 7th 2022, NCP Flanders organised an info session on security-related topics within the European Defence Fund, Horizon Europe (Civil Security for Society) and Digital Europe (Cybersecurity).
The session aims to provide an overview on funding opportunities for researchers, companies and practitioners.
Agenda:
Pick a topic from the menu to get started.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
